In ‘Remission as a Goal in Psoriasis,’ our panel explores the practical realities of defining and sustaining remission in psoriasis, focusing on whether ambitious treatment goals are both achievable and meaningful in clinical practice. The faculty examine the evolving concept of on-treatment remission, acknowledging that while complete clearance may appear stringent, it reflects what is increasingly possible with modern therapies. Rather than serving as a rigid benchmark, remission is framed as an attainable goal that can guide treatment decisions and patient conversations.

The discussion emphasizes that remission is not solely about achieving clear skin but also about maintaining it over time. The panelists highlight the distinction between initial response and sustained disease control, noting that some patients may experience loss of response despite early success. This underscores the importance of ongoing monitoring, treatment adjustments, and a proactive approach to care.

The conversation centers on the patient experience, illustrating how even minimal residual disease can significantly impact quality of life. By addressing these concerns directly, clinicians can better align treatment goals with patient priorities. The faculty also explores the broader benefits of sustained disease control, including potential improvements in mental health and reduction in comorbidity risk. Ultimately, they highlight remission as a tool to overcome therapeutic inertia and encourage clinicians to pursue strategies that aim not only for improvement, but for long-term, meaningful disease control.

Our next episode, ‘Patient Perspectives in Psoriasis Remission,’ the expert dermatologists examine how remission in psoriasis is defined from both clinical and patient perspectives, highlighting the gap between objective clearance and lived experience. It emphasizes the importance of balancing efficacy, comorbidities, and patient-reported outcomes to guide individualized, remission-focused care.